Avelox (moxifloxacin)

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 2: Line 2:
== Structure ==
== Structure ==
Moxifloxacin is a synthetic antimicrobial fluoroquinolone with the molecular formula C<sub>21</sub>H<sub>24</sub>FN<sub>3</sub>O<sub>4</sub>. It has an average molecular weight of 401.438 g/mol '''<ref> https://pubchem.ncbi.nlm.nih.gov/compound/moxifloxacin#section=2D-Structure </ref>'''. Fluoroquinolones are organic compounds categorized as a quinoline, aromatic ring with a substituted carboxyl group at one or more positions, as well as a fluoride as a central part of the compound '''<ref> https://drugsdetails.com/moxifloxacin/#Pharmacophore_structure_Information_about_the_chemical_structure_of_the_drug</ref>'''. The compound is able to accept eight hydrogen bonds and donate two '''<ref> https://pubchem.ncbi.nlm.nih.gov/compound/moxifloxacin#section=2D-Structure </ref>'''. The structure of the drug can also be found as a form of a monohydrochloride salt '''<ref> https://drugsdetails.com/moxifloxacin/#Pharmacophore_structure_Information_about_the_chemical_structure_of_the_drug</ref>'''.
Moxifloxacin is a synthetic antimicrobial fluoroquinolone with the molecular formula C<sub>21</sub>H<sub>24</sub>FN<sub>3</sub>O<sub>4</sub>. It has an average molecular weight of 401.438 g/mol '''<ref> https://pubchem.ncbi.nlm.nih.gov/compound/moxifloxacin#section=2D-Structure </ref>'''. Fluoroquinolones are organic compounds categorized as a quinoline, aromatic ring with a substituted carboxyl group at one or more positions, as well as a fluoride as a central part of the compound '''<ref> https://drugsdetails.com/moxifloxacin/#Pharmacophore_structure_Information_about_the_chemical_structure_of_the_drug</ref>'''. The compound is able to accept eight hydrogen bonds and donate two '''<ref> https://pubchem.ncbi.nlm.nih.gov/compound/moxifloxacin#section=2D-Structure </ref>'''. The structure of the drug can also be found as a form of a monohydrochloride salt '''<ref> https://drugsdetails.com/moxifloxacin/#Pharmacophore_structure_Information_about_the_chemical_structure_of_the_drug</ref>'''.
-
[[Image:Moxiflox.png]]<ref>14614666</ref>
+
[[Image:Moxiflox.png]]<ref> https://pubchem.ncbi.nlm.nih.gov/compound/moxifloxacin#section=2D-Structure </ref>
-
[[Image:Moxi 3d.png]]<ref>14614666</ref>
+
[[Image:Moxi 3d.png]]<ref> https://pubchem.ncbi.nlm.nih.gov/compound/moxifloxacin#section=2D-Structure </ref>
== Function ==
== Function ==
-
Moxifloxacin is a fluoroquinolone antibiotic that also acts as an antibacterial compound '''<ref> https://pubchem.ncbi.nlm.nih.gov/compound/moxifloxacin#section=2D-Structure </ref>'''. The drug is typically taken in 400mg tablets daily, ranging from five to fourteen days. When dealing with more severe infections, moxifloxacin is administered in 400mg through intravenous injections '''<ref> https://livertox.nlm.nih.gov//Moxifloxacin.htm </ref>'''. Moxifloxacin is active against gram-positive and gram-negative bacteria with an increased affinity for gram-positive bacteria, such as the multidrug-resistant strains of ''Streptococcus pneumoniae'' '''<ref> https://livertox.nlm.nih.gov//Moxifloxacin.htm </ref>'''. Other examples of infections for which moxifloxacin is prescribed include bronchitis, sinusitis, skin or soft tissue infection, anthrax prophylaxis, and tuberculosis '''<ref> https://www.drugs.com/avelox.html</ref>'''. The function of moxifloxacin is inhibited by the consumption of cations, but the precise mechanism is unknown. One possible explanation for the decreased function of moxifloxacin in the presence of cations is the binding of cations to the compound causing chelation and results in a decreased amount of drug available to interact with the bacteria. Alternatively, the presence of cations may interact with the drug’s target, DNA <scene name='75/756549/Gyrase/1'>gyrase</scene>, which decreases its effectiveness '''<ref name="ncbi">7868402</ref>'''.
+
Moxifloxacin is a fluoroquinolone antibiotic that also acts as an antibacterial compound '''<ref> https://pubchem.ncbi.nlm.nih.gov/compound/moxifloxacin#section=2D-Structure </ref>'''. The drug is typically taken in 400mg tablets daily, ranging from five to fourteen days. When dealing with more severe infections, moxifloxacin is administered in 400mg through intravenous injections '''<ref> https://livertox.nlm.nih.gov//Moxifloxacin.htm </ref>'''. Moxifloxacin is active against gram-positive and gram-negative bacteria with an increased affinity for gram-positive bacteria, such as the multidrug-resistant strains of ''Streptococcus pneumoniae'' '''<ref> https://livertox.nlm.nih.gov//Moxifloxacin.htm </ref>'''. Other examples of infections for which moxifloxacin is prescribed include bronchitis, sinusitis, skin or soft tissue infection, anthrax prophylaxis, and tuberculosis '''<ref> https://www.drugs.com/avelox.html</ref>'''. The function of moxifloxacin is inhibited by the consumption of cations, but the precise mechanism is unknown. One possible explanation for the decreased function of moxifloxacin in the presence of cations is the binding of cations to the compound causing chelation and results in a decreased amount of drug available to interact with the bacteria. Alternatively, the presence of cations may interact with the drug’s target, DNA <scene name='75/756549/Gyrase/1'>gyrase</scene>, which decreases its effectiveness '''<ref> https://www.ncbi.nlm.nih.gov/pubmed/7868402 </ref>'''.
== Mechanism ==
== Mechanism ==
Moxifloxacin is an antibiotic that works by inhibiting the function of two bacterial enzymes, topoisomerase II (DNA Gyrase) and topoisomerase IV, both of which are necessary for bacterial DNA replication '''<ref> https://www.drugbank.ca/drugs/DB00218</ref>'''. DNA Gyrase works by inducing supercoils in DNA, and by unwinding DNA during replication, thus relieving torsional stress as helicase separates the double strand. '''<ref name="ncbi">NBK21703</ref>''' Topoisomerase IV causes decatenation, the unlinking of strands of tangled DNA, a function also necessary for DNA replication '''<ref> https://academic.oup.com/nar/article/44/10/4528/2516939/How-topoisomerase-IV-can-efficiently-unknot-and</ref>'''. Moxifloxacin is taken up by human phagocytic leukocytes, such as neutrophils and macrophages, where it remains active against obligate intracellular bacterial pathogens '''<ref> http://aac.asm.org/content/43/1/12.full </ref>'''. Moxifloxacin, like other quinolones, may be able to enter bacterial cells through porins, which are small beta-barrel channels through their membranes '''<ref> https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2696358/ </ref>'''. Moxifloxacin can then bind directly to its target, topoisomerase. Topoisomerases work by binding to a <scene name='75/756549/Dna_backbone/1'>DNA</scene> segment, called a G segment, and simultaneously binding a second DNA segment called the T segment. Topoisomerase cleaves the G segment, passes the T segment through the cleaved G segment, and then ligates the G segment back together. Topoisomerases require a magnesium ion for the cleavage of the G segment. Moxifloxacin prevents the action of topoisomerases by coordinating two bonds to a serine and a glutamic acid present on the enzyme using the <scene name='75/756549/Magnesium/3'>magnesium ion</scene> and associated water molecules. By this mechanism, Moxifloxacin is able to modulate the activity of the bacterial topoisomerase '''<ref> http://vanderbilt.edu/vicb/DiscoveriesArchives/combatting_antibiotic_drug_resistance.html </ref>'''.
Moxifloxacin is an antibiotic that works by inhibiting the function of two bacterial enzymes, topoisomerase II (DNA Gyrase) and topoisomerase IV, both of which are necessary for bacterial DNA replication '''<ref> https://www.drugbank.ca/drugs/DB00218</ref>'''. DNA Gyrase works by inducing supercoils in DNA, and by unwinding DNA during replication, thus relieving torsional stress as helicase separates the double strand. '''<ref name="ncbi">NBK21703</ref>''' Topoisomerase IV causes decatenation, the unlinking of strands of tangled DNA, a function also necessary for DNA replication '''<ref> https://academic.oup.com/nar/article/44/10/4528/2516939/How-topoisomerase-IV-can-efficiently-unknot-and</ref>'''. Moxifloxacin is taken up by human phagocytic leukocytes, such as neutrophils and macrophages, where it remains active against obligate intracellular bacterial pathogens '''<ref> http://aac.asm.org/content/43/1/12.full </ref>'''. Moxifloxacin, like other quinolones, may be able to enter bacterial cells through porins, which are small beta-barrel channels through their membranes '''<ref> https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2696358/ </ref>'''. Moxifloxacin can then bind directly to its target, topoisomerase. Topoisomerases work by binding to a <scene name='75/756549/Dna_backbone/1'>DNA</scene> segment, called a G segment, and simultaneously binding a second DNA segment called the T segment. Topoisomerase cleaves the G segment, passes the T segment through the cleaved G segment, and then ligates the G segment back together. Topoisomerases require a magnesium ion for the cleavage of the G segment. Moxifloxacin prevents the action of topoisomerases by coordinating two bonds to a serine and a glutamic acid present on the enzyme using the <scene name='75/756549/Magnesium/3'>magnesium ion</scene> and associated water molecules. By this mechanism, Moxifloxacin is able to modulate the activity of the bacterial topoisomerase '''<ref> http://vanderbilt.edu/vicb/DiscoveriesArchives/combatting_antibiotic_drug_resistance.html </ref>'''.

Revision as of 23:32, 17 April 2017

Crystal structure of Moxifloxacin, DNA and a Baumannii Topo IV

Drag the structure with the mouse to rotate

References

  1. https://pubchem.ncbi.nlm.nih.gov/compound/moxifloxacin#section=2D-Structure
  2. https://drugsdetails.com/moxifloxacin/#Pharmacophore_structure_Information_about_the_chemical_structure_of_the_drug
  3. https://pubchem.ncbi.nlm.nih.gov/compound/moxifloxacin#section=2D-Structure
  4. https://drugsdetails.com/moxifloxacin/#Pharmacophore_structure_Information_about_the_chemical_structure_of_the_drug
  5. https://pubchem.ncbi.nlm.nih.gov/compound/moxifloxacin#section=2D-Structure
  6. https://pubchem.ncbi.nlm.nih.gov/compound/moxifloxacin#section=2D-Structure
  7. https://pubchem.ncbi.nlm.nih.gov/compound/moxifloxacin#section=2D-Structure
  8. https://livertox.nlm.nih.gov//Moxifloxacin.htm
  9. https://livertox.nlm.nih.gov//Moxifloxacin.htm
  10. https://www.drugs.com/avelox.html
  11. https://www.ncbi.nlm.nih.gov/pubmed/7868402
  12. https://www.drugbank.ca/drugs/DB00218
  13. NBK21703
  14. https://academic.oup.com/nar/article/44/10/4528/2516939/How-topoisomerase-IV-can-efficiently-unknot-and
  15. http://aac.asm.org/content/43/1/12.full
  16. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2696358/
  17. http://vanderbilt.edu/vicb/DiscoveriesArchives/combatting_antibiotic_drug_resistance.html
  18. http://vanderbilt.edu/vicb/DiscoveriesArchives/combatting_antibiotic_drug_resistance.html
  19. https://pubchem.ncbi.nlm.nih.gov/compound/moxifloxacin#section=Chemical-and-Physical-Properties
  20. https://drugsdetails.com/moxifloxacin/#Pharmacophore_structure_Information_about_the_chemical_structure_of_the_drug
  21. https://www.drugs.com/avelox.html

(1)https://pubchem.ncbi.nlm.nih.gov/compound/moxifloxacin#section=Chemical-and-Physical-Properties (2)https://drugsdetails.com/moxifloxacin/#Pharmacophore_structure_Information_about_the_chemical_structure_of_the_drug (3)https://livertox.nlm.nih.gov//Moxifloxacin.htm (4)https://www.drugs.com/avelox.html (5)https://www.ncbi.nlm.nih.gov/pubmed/7868402 6. https://www.drugbank.ca/drugs/DB00218 7. https://www.ncbi.nlm.nih.gov/books/NBK21703/ 8.https://academic.oup.com/nar/article/44/10/4528/2516939/How-topoisomerase-IV-can-efficiently-unknot-and 9. http://aac.asm.org/content/43/1/12.full 10. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2696358/ 11.http://vanderbilt.edu/vicb/DiscoveriesArchives/combatting_antibiotic_drug_resistance.html Photographs :Ginsburg AS, Hooper N, Parrish N, Dooley KE, Dorman SE, Booth J, Diener-West M, Merz WG, Bishai WR, Sterling TR: Fluoroquinolone resistance in patients with newly diagnosed tuberculosis. Clin Infect Dis. 2003 Dec 1;37(11):1448-52. Epub 2003 Nov 4.

Proteopedia Page Contributors and Editors (what is this?)

Brandon Ozmer, Samantha Rimer, Michal Harel

Personal tools